ISSN: 2454-9940

INTERNATIONAL JOURNAL OF APPLIED SCIENCE ENGINEERING AND MANAGEMENT

E-Mail :
editor.ijasem@gmail.com
editor@ijasem.org

www.ijasem.org

INTERNATIONAL JOURNAL OF APPLIED SCIENCE ENGINEERING AND MANAGEMENT

ISSN2454-9940www.ijsem.org

Vol 20, Issuse.1 Mar 2026

https://doi.org/10.5281/zenodo.18879138

Biodegradable Polymer Nano Composites for Controlled Drug Delivery with Self-Regulated Ph-Responsive Mechanisms

B.srinivas,
Assistant Professor, M.sc , chemistry, Siddhartha institute of technology and science Autonomous

ABSTRACT

Biodegradable polymer nanocomposites are exciting new materials for controlled drug delivery because of their controllability over disintegration rate, surface area, and reactivity to physiological cues. The sensitivity to variations in pH is more noticeable in diseased tissues compared to healthy ones, such as the tumor microenvironment, inflammatory regions, and the gastrointestinal system, where changes in pH are more pronounced. Producing biodegradable polymer nanocomposites with pH-dependent drug release rates is the focus of this research. Biodegradable and pH-responsive materials will be used to fabricate these composites. Pharmacological models were loaded onto a wide variety of biodegradable polymers and nanofillers after they were developed, investigated (FTIR, SEM/TEM, XRD), and tested. Surfaces or backbones of nanofiller materials were modified with pH-sensitive functional groups, such as carboxylic acid or amine. In vitro drug release profiles demonstrated a substantial pH dependence, with faster release at pH 5.0 (matching the tumor microenvironment) and sustained release at pH 7.4 (normal tissue). Tests for biocompatibility showed that there was little cytotoxicity. The findings suggest that the engineered nanocomposites may provide controlled drug release by pH-driven protonation/deprotonation, bond cleavage, or reversible swelling. These technologies show great promise in wound healing, oral delivery systems, and personalized cancer therapy, according to the results. The main focus of future research will be to validate in vivo and include multi-stimuli response.

Keywords: Biodegradable polymer nanocomposites; Controlled drug delivery; pH-responsive drug release; Self-regulated release mechanism

INTRODUCTION

The less-than-ideal therapeutic benefits and increased toxicity caused by changes in drug concentration are common results of traditional pharmaceutical administration techniques. Due to their ability to distribute medications in a regulated, targeted, and sustained manner, nanocarriers composed of biodegradable polymers have lately garnered significant attention as a possible remedy to these issues. Studies on polymers such as chitosan and polylactic-co-glycolic acid (PLGA) have focused on their biocompatibility, non-toxic breakdown products, and changeable physicochemical properties. These materials spontaneously dissolve inside the body, eliminating the need for surgical removal and reducing the likelihood of long-term complications.

By adding nanofillers to biodegradable polymer nanocomposites, scientists have been able to improve their mechanical strength, drug loading capacity, and release control. Nanoparticles having functional groups and large surface areas, such as graphene oxide and mesoporous silica nanoparticles, may bind strongly to drug molecules and polymer chains. With these hybrid systems, not only can the structural stability be improved, but the rate of drug delivery can also be carefully controlled. One promising smart delivery approach is the stimuli-responsive system, which responds to physiological cues such as pH, enzyme activity, and temperature.

In cancer therapy, pH-responsive drug delivery systems are especially attractive since the tumor microenvironment is relatively acidic (pH 5.0-6.8) compared to normal physiological pH (7.4). Nanocomposites may self-regulate the release of

medici ne in response to changes in ambient pH by including acid-labile linkages or ionizable functional groups into the polymer matrix. In neutral situations, the carrier remains stable and releases the medicine slowly. However, in acidic environments, the swelling and quicker drug diffusion are caused by protonation and bond breakdown. The selective release method allows the medication to accumulate more efficiently in diseased locations while causing less damage to healthy tissues. Therefore, biodegradable polymer nanocomposites with pH-responsive processes could be an intelligent and useful platform for targeted and efficient medication delivery.

LITERATURE SURVEY

Biodegradable polymer-based drug delivery systems have attracted a lot of attention over the last decade due to their promise to improve therapeutic effectiveness while reducing systemic toxicity. Many applications have been made possible by polymers such as polylactic-co-glycolic acid (PLGA) because of its favorable biocompatibility, predictable degradation profile, and approval by the Food and Drug Administration. Researchers have demonstrated that PLGA nanoparticles may be optimized for prolonged drug release by adjusting the particle size, molecular weight, and lactide-to-glycolide ratio. However, conventional PLGA systems often do not react to environmental signals, leading to the unintended release of medications into healthy tissues.

Natural polymers like chitosan, which are intrinsically sensitive to pH, have being explored as possible alternatives to these limitations. Chitosan comprises primary amine groups, which cause it to expand and become more acid-permeable. Several research have shown that chitosan-based nanoparticles release more medicine when exposed to acidic conditions mimicking tumors, as opposed to neutral physiological pH. This is why chitosan is a promising material for cancer drug delivery systems. Its mucoadhesiveness and biodegradability further enhance its biomedical applicability.

Scientists have lately shown a great deal of interest in polymer nanocomposites, which integrate biodegradable matrices with nanofillers. The mechanical reinforcing capability, large surface area, and availability of oxygen-containing functional groups in nanomaterials such as graphene oxide have made them rather intriguing. The efficiency of drug loading may be improved by graphene oxide via hydrogen bonding and π-π stacking interactions, according to research. In addition, structures are made more stable and the rate of release may be more precisely controlled when combined with biodegradable polymers.

A lot of work has been gone into developing hybrid nanocarriers using mesoporous silica nanoparticles (MSNs). Their large internal surface area and adjustable pore size allow for very efficient drug encapsulation. Researchers have functionalized MSNs with acid-sensitive linkers to achieve pH-triggered release in tumor microenvironments. These nanofillers, when combined with polymer matrices, form composite systems that may be manipulated to release their contents via two different mechanisms: diffusion and bond cleavage.

METHODOLOGY

There are many steps involved in putting the pH-responsive medication delivery system into action:

1. Material preparation
2. Nanoparticle fabrication
3. Drug loading
4. Characterization
5. Release testing
6. Biological evaluation

At Physiological pH (7.4)

- Polymer chains remain compact.
- Minimal protonation of amine groups.
- Slow diffusion-controlled drug release.

At Acidic pH (5.0–6.5)

- Protonation of $–NH_2$ groups increases swelling.
- Hydrazone bonds cleave.
- Increased porosity and rapid drug release.

$$EE\% = \frac{W_t - W_f}{W_t} \times 100$$

Where :

- WtW_tWt = Total drug added
- WfW_fWf = Free (unencapsulated) drug

For controlled drug delivery with self-regulated pH-responsive mechanisms, biodegradable polymer nanocomposites were constructed using an experimentally validated and systematic process. Overall, the system was designed to be stable at physiological pH levels (pH 7.4) and to release drugs rapidly in acidic environments (pH 5.0-6.5), such as tumor tissues. Materials synthesis, nanocomposite manufacturing, drug encapsulation, characterization, and biological validation are all steps in the implementation process.

$$\text{R-NH}_2 + H^+ \rightarrow \text{R-NH}_3^+$$

We started by selecting biodegradable polymers like chitosan and polylactic-co-glycolic acid (PLGA) because to their biocompatibility and inherent degradability. Chitosan was rendered pH sensitive by its protonable amine groups, whereas PLGA provided structural stability and continual disintegration. To enhance the drug loading capacity and mechanical strength, the polymer matrix was supplemented with nanofillers, namely graphene oxide and mesoporous silica nanoparticles. There was an interaction between the polymer and the drug molecules because of the functional groups and large surface area provided by these nanofillers. The nanocomposite was created using emulsion solvent evaporation as its fabrication procedure. To create an aqueous phase containing chitosan, PLGA was first dissolved in an organic solvent and then homogenized at high speeds. To avoid clumping, the nanofillers were ultrasonically distributed before being added to the emulsion mixture. Evaporation of the solvent allowed stable nanoscale composite particles to form. The nanoparticles were collected after centrifugation and freeze-dried to produce a dry powder for future studies. The chemotherapeutic agent doxorubicin served as a paradigm for the drug encapsulation process. The addition of the medication during nanoparticle formation ensured that it would be uniformly distributed throughout the polymeric matrix. The encapsulation efficiency was optimized by adjusting the polymer content, homogenization speed, and nanofiller ratio. The enhanced formulation achieved the maximum drug loading capacity and guaranteed long-term encapsulation without any leakage.

The self-regulating pH-responsive system used protonation and bond-cleavage ideas. Due to limited ionization of functional groups, the polymer network remained compact, allowing for slow diffusion-controlled drug release at a physiological pH of 7.4. When the amine groups of chitosan were protonated in an acidic environment (pH 5.0), electrostatic repulsion developed inside the polymer matrix. This caused the nanocomposite structure to expand, which widened the pores and accelerated the drug's diffusion. The drug release was much faster in acidic environments because the polymer backbone included acid-labile linkages that cleaved. This two-step procedure ensured that the drug release was autonomous and self-regulating, free from any external influences.

There was an opportunity to assess the nanoparticles' biological utility via in vitro testing using both cancer and normal cell lines. By exposing the nanocomposites to buffer solutions that mimicked both normal and abnormal tumor environments, we were able to evaluate their release kinetics. Contrary to expectations, the results demonstrated that drug release was much higher in acidic environments compared to neutral ones. Research on cytotoxicity has shown that when cells are exposed to acidic conditions, the amount of drugs within them rises. This leads to a selective toxicity that affects cancer cells but has no impact on healthy cells. In real-world therapeutic contexts, the established system is tailored for intravenous administration. As the nanoparticles travel through the bloodstream, where the pH is about 7.4, after injection, they preserve their structural integrity and delay the drug's loss to the circulation. Increased permeability and retention (EPR) causes the material to concentrate in tumor tissues, which triggers the pH-responsive process. This is particularly true in the slightly acidic tumor microenvironment. Due of its swelling, delayed breakdown, and localized drug release, the nanocomposite improves therapeutic effectiveness while reducing systemic side effects. The capability for long-term storage was further guaranteed by stability testing. After being periodically evaluated at controlled temperatures, the freeze-dried nanoparticles showed no signs of aggregation or medication breakdown. The system's potential medicinal applications were shown by its capacity to maintain structure and release performance over extended durations.

ISSN2454-9940www.ijsem.org

Vol 20, Issuse.1 Mar 2026

A review of the literature reveals that the pH-responsive nanocomposite system is effective, biocompatible, and capable of self-regulating medication administration. The combination of biodegradable polymers with functional nanofillers enables the technology to have configurable release behavior, making it ideal for targeted cancer therapy and other pH-dependent biomedical applications.
PLGA degradation follows hydrolysis:

$$\text{Ester Bond} + H_2O \rightarrow \text{Carboxylic Acid} + \text{Alcohol}$$

Cancer Treatment Application

- Nanoparticles administered intravenously.
- Float through the bloodstream at a pH of 7.4.Through the Enhanced Permeability and Retention (EPR) effect, they accumulate in tumor tissue.
- Accelerated release is triggered by an acidic tumor microenvironment.

Stability and Storage

- We evaluated the stability at both 4°C and 25°C.
- Particles did not aggregate significantly after three months.
- The drug retention rate is more than 90%.

RESULTS AND DISCUSSION

Experimental evaluation of biodegradable polymer nanocomposites demonstrated successful production, effective drug encapsulation, and controlled pH-responsive drug release characteristics. In physiological (pH 7.4) and acidic (pH 5.0) settings, the system's release patterns differed dramatically, indicating its ability to self-regulate.

Drug loading capacity (DLC%) was calculated as:

$$DLC\% = \frac{W_d}{W_n} \times 100$$

Where:
WdW_dWd = Encapsulated drug weight
WnW_nWn = Total nanoparticle weight

Observed DLC: 14–18%

Transmission electron microscopy (TEM) and scanning electron microscopy (SEM) confirmed that the synthesized nanoparticles were spherical and had a uniform size distribution. Usually ranging from 150 to 220 nm in size, the particles were precisely calibrated to target tumors using the EPR effect. Although graphene oxide and mesoporous silica nanoparticles did not significantly alter particle shape, they improved structural stability and drug loading capabilities.

Nanocomposite materials that were loaded with doxorubicin showed:

- **Encapsulation Efficiency (EE%)**: 78–85%
- **Drug Loading Capacity (DLC%)**: 14–18%

Strong drug-polymer-nanofiller interaction is confirmed by the excellent encapsulation efficiency.
cell viability (%) was calculated as:

$$Cell\ Viability = \frac{Abs_{sample}}{Abs_{control}} \times 100$$

Research on the release of drugs in vitro was carried out at: A physiological state with a pH of 7.4• A pH of 5.0 (environment around tumor) The nanocomposite maintained its compact structure at a pH of 7.4, and the release of the medication was gradual and continuous, reaching around 35-40% after 72 hours. The protonation of the chitosan amine groups caused the medication to be released more quickly (about 80-90% within 48-72 hours) at a pH of 5.0, leading to rapid swelling and bond cleavage. The fact that drug diffusion is automatically activated by acidic conditions lends credence to the self-regulated release mechanism.
Research on the release of drugs was carried out over a 72-hour period at pH 5.0 and pH 7.4.

Experimental Release Results:

- **pH 7.4:** ~40% release after 72 hrs
- **pH 5.0:** ~85% release after 72 hrs

Various kinetic models were used to fit the drug release data.

Parameter	Experimental Outp
Particle Size	150–220 nm
Zeta Potential	+22 to +28 mV
Encapsulation Efficiency	78–85%
Drug Release at pH 7.4	~40% (72 hrs)
Drug Release at pH 5.0	~85% (72 hrs)
Normal Cell Viability	>90%
Cancer Cell Inhibition	Significant

The results prove that biodegradable polymer nanocomposites are effective and selective drug delivery systems. The pH-responsive method minimizes the risk of pharmaceutical release into the bloodstream before it reaches tumor sites, enabling rapid medication delivery. The breakdown of the polymer and the swelling caused by protonation are combined to provide dual control over the release kinetics. Important pH-sensitive biological applications, such personalized cancer therapy, stand to benefit greatly from this study.

CONCLUSION

Having pH-responsive systems in biodegradable polymer nanocomposites may considerably improve the controlled release of pharmaceuticals. Because acidic circumstances caused fast release, they were more promising for tumor-targeted therapy. Additional in vivo experiments and tuning might potentially enhance clinical applicability.

REFERENCES

[1]. Zhang, Y., Liu, J., & Chen, X. (2022). pH-responsive biodegradable polymeric nanoparticles for targeted cancer therapy. *Journal of Controlled Release*, 349, 935–954.

[2]. Wang, L., Huang, Y., & Li, Z. (2022). Self-regulated drug delivery systems based on acid-labile polymer nanocomposites. *ACS Applied Materials & Interfaces*, 14(18), 21045–21059.

[3]. Kim, H. J., Park, J. W., & Lee, S. (2022). Biodegradable nanocarriers with tunable pH sensitivity for enhanced intracellular drug delivery. *Biomacromolecules*, 23(6), 2448–2461.

[4]. Patel, R., Shah, D., & Patel, M. (2023). Chitosan-based nanocomposites for pH-triggered anticancer drug delivery: Recent advances. *International Journal of Biological Macromolecules*, 233, 123467.

[5]. Li, Q., Zhao, H., & Sun, W. (2023). Mesoporous silica–polymer hybrid nanocomposites for controlled drug release in tumor microenvironment. *Materials Science and Engineering C*, 145, 113204.

[6]. Ahmed, T. A., & Aljaeid, B. M. (2023). Development of biodegradable polymeric nanoparticles for sustained and stimuli-responsive drug delivery. *Pharmaceutics*, 15(4), 1089.

[7]. Chen, R., Gao, X., & Xu, P. (2023). Acid-sensitive polymer–graphene oxide nanocomposites for targeted chemotherapy. *Chemical Engineering Journal*, 452, 139278.

[8]. Singh, N., Kumar, R., & Mehta, S. (2024). Smart biodegradable nanocomposite systems for tumor-selective drug release. *Advanced Drug Delivery Reviews*, 204, 114682.

[9]. Torres, M., & Gutierrez, L. (2024). Design of pH-responsive PLGA nanocarriers for improved cancer therapeutics. *European Journal of Pharmaceutics and Biopharmaceutics*, 188, 102–118.

[10]. Zhou, J., Yang, Y., & Wang, C. (2024). Self-adaptive polymer nanocomposites for stimuli-responsive drug delivery. *Nano Today*, 53, 101998.

[11]. Rahman, M. M., Islam, M. A., & Park, K. (2024). Advances in biodegradable pH-sensitive nanocarriers for anticancer drug delivery. *Drug Delivery and Translational Research*, 14, 756–775.

[12]. Gupta, A., Sharma, P., & Verma, S. (2025). Emerging biodegradable polymeric nanocomposites for controlled and targeted drug release. *Journal of Nanobiotechnology*, 23, 41.

[13]. Huang, X., Li, D., & Chen, G. (2025). Dual pH-responsive polymer–silica

nanoc omposites for enhanced intracellular drug delivery. *ACS Nano*, 19(2), 2456–2472.

[14]. Lee, S. Y., Kim, J., & Choi, H. (2025). Tumor microenvironment-responsive biodegradable nanocarriers: Current progress and future perspectives. *Advanced Functional Materials*, 35(6), 2409821.

[15]. Kumar, V., Reddy, K. R., & Rao, P. (2025). Smart polymer–graphene oxide nanocomposites for selective cancer therapy. *Materials Today Bio*, 26, 100978.